Dermacyte story correction
This article was originally published in The Rose Sheet
Executive Summary
Oxygen Biotherapeutics is planning clinical trials for the use of its Oxycyte technology for OTC products that treat wounds, burns and acne, but is not currently involved in clinical trials, as reported in "The Rose Sheet" Nov. 2, 2009. The firm will seek FDA approval for the applications, after which it hopes to introduce the formulas. Additionally, the Durham, N.C.-based company has been researching the Oxycyte concept in medical indications for 19 years, and has not been working to develop a cosmetic application for that length of time, as reported in the story. "The Rose Sheet" regrets the errors